Reneo Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Onkure Therapeutics

10/08/2023 14:32

* Reneo Pharmaceuticals Inc  RPHM.OQ  reported a quarterly
adjusted loss of 65 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 52 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Reneo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 65 cents​.
    * The mean earnings estimate of analysts had risen by
about 5.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Reneo Pharmaceuticals Inc shares had risen by 1.2% this
quarter and gained 185.0% so far this year.
    * The company reported a quarterly loss of $19.53 million.
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $24.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.52          -0.65          Missed
 Mar. 31 2023      -0.60          -0.60          Met
 Dec. 31 2022      -0.60          -0.56          Beat
 Sep. 30 2022      -0.57          -0.53          Beat